SHAREHOLDER ALERT: Weiss Law Investigates Epizyme, Inc.

NEW YORK, June 27, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Epizyme, Inc. ("Epizyme" or the "Company") (NASDAQ: EPZM), in connection with the proposed acquisition of the Company by Ipsen S.A. (Euronext: IPN; ADR: IPSEY) via tender offer. Under the terms of the merger agreement, the Company's shareholders will receive $1.45 in cash, plus one contingent value right (CVR) for each share of Epizyme common stock owned.